 |
 |

COMMENTS AND OPINIONS
Estimating Cardiovascular Risk
Bastian M. Seidel, MD, MRCGP, FRACGP;
Nigel Stocks, BSc, MBBS, MD, Dip PH, FRACGP, FAFPHM
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
In the May 28th issue of the Archives, Weymiller et al1 highlight the significant benefit of patient-tailored decision aids on adherence to statin therapy in patients with type 2 diabetes mellitus. They also report that patients who used the decision aid were estimating their own cardiovascular risk and potential absolute cardiovascular risk reduction more accurately, indicating the importance of specifically designed decision aids to enhance knowledge and understanding of cardiovascular risk.
However, for estimating cardiovascular risk the authors used a pen-and-paper risk estimator based on data from the United Kingdom Prospective Diabetes Study (UKPDS).2 This risk estimator calculates the coronary heart disease (CHD) risk rather than cardiovascular disease (CVD) risk.3 However, CVD is a combined end point of CHD (fatal and nonfatal myocardial infarction and new angina) plus stroke (fatal and nonfatal stroke and . . . [Full Text of this Article] AUTHOR INFORMATION
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED LETTER
Estimating Cardiovascular Risk—Reply
Audrey Weymiller and Victor M. Montori
Arch Intern Med. 2008;168(1):111.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Helping Patients With Type 2 Diabetes Mellitus Make Treatment Decisions: Statin Choice Randomized Trial
Audrey J. Weymiller, Victor M. Montori, Lesley A. Jones, Amiram Gafni, Gordon H. Guyatt, Sandra C. Bryant, Teresa J. H. Christianson, Rebecca J. Mullan, and Steven A. Smith
Arch Intern Med. 2007;167(10):1076-1082.
ABSTRACT
| FULL TEXT
|